Clinical Aspects of STAT3 Gain-of-Function Germline Mutations: A Systematic Review

The Journal of Allergy and Clinical Immunology: In Practice - Tập 7 Số 6 - Trang 1958-1969.e9 - 2019
Alexandre Fabre1,2, Sarah Marchal3, Vincent Barlogis4, Bernard Mari5, Pascal Barbry5, Pierre Bordigoni6,7, Lisa R. Forbes8, Tiphanie P. Vogel8, Lisa Giovannini‐Chami3,7
1Aix-Marseille University, Inserm, GMGF, Marseille, France
2Pediatric Multidisciplinary Pediatric APHM, Timone Enfant, Marseille, France
3Pediatric Pulmonology Department, Hôpitaux pédiatriques de Nice CHU-Lenval, Nice, France
4Pediatric Hematology Department, APHM, Timone Enfant, Marseille, France
5Université Côte d’Azur, CNRS, IPMC, Valbonne, France
6Pediatric Hematology Department, CHU de Nice, Nice, France
7Université de Nice-Sophia Antipolis, Nice, France
8Department of Pediatrics, Immunology Allergy and Rheumatology, Baylor College of Medicine, Center for Human Immunobiology, Texas Children's Hospital, Houston, Texas

Tóm tắt

Từ khóa


Tài liệu tham khảo

Flanagan, 2014, Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease, Nat Genet, 46, 812, 10.1038/ng.3040

Holland, 2007, STAT3 mutations in the hyper-IgE syndrome, N Engl J Med, 357, 1608, 10.1056/NEJMoa073687

Vogel, 2015, The ying and yang of STAT3 in human disease, J Clin Immunol, 35, 615, 10.1007/s10875-015-0187-8

Milner, 2015, Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations, Blood, 125, 591, 10.1182/blood-2014-09-602763

Hillmer, 2016, STAT3 signaling in immunity, Cytokine Growth Factor Rev, 31, 1, 10.1016/j.cytogfr.2016.05.001

Haapaniemi, 2015, Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3, Blood, 125, 639, 10.1182/blood-2014-04-570101

Forbes, 2018, Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations, J Allergy Clin Immunol, 142, 1665, 10.1016/j.jaci.2018.07.020

Lek, 2016, Analysis of protein-coding genetic variation in 60,706 humans, Nature, 536, 285, 10.1038/nature19057

Bennett, 2017, ExACtly zero or once: a clinically helpful guide to assessing genetic variants in mild epilepsies, Neurol Genet, 3, e163, 10.1212/NXG.0000000000000163

Wienke, 2015, A novel human STAT3 mutation presents with autoimmunity involving Th17 hyperactivation, Oncotarget, 6, 20037, 10.18632/oncotarget.5042

Maffucci, 2016, Genetic diagnosis using whole exome sequencing in common variable immunodeficiency, Front Immunol, 7, 220, 10.3389/fimmu.2016.00220

Haddad, 2015, STAT3: too much may be worse than not enough!, Blood, 125, 583, 10.1182/blood-2014-11-610592

Lau, 2016, Pulmonary manifestations of the autoimmune lymphoproliferative syndrome. A retrospective study of a unique patient cohort, Ann Am Thorac Soc, 13, 1279, 10.1513/AnnalsATS.201601-079OC

Khoury, 2017, Tocilizumab promotes regulatory T-cell alleviation in STAT3 gain-of-function–associated multi-organ autoimmune syndrome, Clin Ther, 39, 444, 10.1016/j.clinthera.2017.01.004

Weinreich, 2017, Up, down, and all around: diagnosis and treatment of novel STAT3 variant, Front Pediatr, 5, 49, 10.3389/fped.2017.00049

Sediva, 2017, Short stature in a boy with multiple early-onset autoimmune conditions due to a STAT3 activating mutation: could intracellular growth hormone signalling be compromised?, Horm Res Paediatr, 88, 160, 10.1159/000456544

Nabhani, 2017, STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds, Clin Immunol Orlando Fla, 181, 32, 10.1016/j.clim.2017.05.021

Velayos, 2017, An activating mutation in STAT3 results in neonatal diabetes through reduced insulin synthesis, Diabetes, 66, 1022, 10.2337/db16-0867

Besnard, 2018, Pediatric-onset Evans syndrome: heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations, Clin Immunol, 188, 52, 10.1016/j.clim.2017.12.009

Fabre, 2018, STAT3 GOF: a new kid on the block in interstitial lung diseases, Am J Respir Crit Care Med, 197, e22, 10.1164/rccm.201707-1500IM

Gutiérrez, 2018, Partial growth hormone insensitivity and dysregulatory immune disease associated with de novo germline activating STAT3 mutations, Mol Cell Endocrinol, 473, 166, 10.1016/j.mce.2018.01.016

Russell, 2018, A novel de novo activating mutation in STAT3 identified in a patient with common variable immunodeficiency (CVID), Clin Immunol Orlando Fla, 187, 132, 10.1016/j.clim.2017.11.007

Takagi, 2018, Genetic heterogeneity of uncharacterized childhood autoimmune diseases with lymphoproliferation, Pediatr Blood Cancer, 65, e26831, 10.1002/pbc.26831

Giovannini-Chami, 2019, STAT3 gain of function: a new aetiology of severe rheumatic disease, Rheumatology, 58, 365, 10.1093/rheumatology/key308

Camarero, 2003, Collagenous colitis in children: clinicopathologic, microbiologic, and immunologic features, J Pediatr Gastroenterol Nutr, 37, 508, 10.1097/00005176-200310000-00020

Schubert, 2014, Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations, Nat Med, 20, 1410, 10.1038/nm.3746

Gámez-Díaz, 2016, The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency, J Allergy Clin Immunol, 137, 223, 10.1016/j.jaci.2015.09.025

Coulter, 2017, Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: a large patient cohort study, J Allergy Clin Immunol, 139, 597, 10.1016/j.jaci.2016.06.021

Neven, 2011, A survey of 90 patients with autoimmune lymphoproliferative syndrome related to TNFRSF6 mutation, Blood, 118, 4798, 10.1182/blood-2011-04-347641

Barzaghi, 2018, Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study, J Allergy Clin Immunol, 141, 1036, 10.1016/j.jaci.2017.10.041

Hwa, 2016, STAT5B deficiency: impacts on human growth and immunity, Growth Horm IGF Res, 28, 16, 10.1016/j.ghir.2015.12.006

Toubiana, 2016, Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotype, Blood, 127, 3154, 10.1182/blood-2015-11-679902

Kofoed, 2003, Growth hormone insensitivity associated with a STAT5b mutation, N Engl J Med, 349, 1139, 10.1056/NEJMoa022926

Pechkovsky, 2012, STAT3-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF, Am J Pathol, 180, 1398, 10.1016/j.ajpath.2011.12.022

Flanagan, 2014, Activating germline mutations in STAT3 cause early-onset multi-organ autoimmune disease, Nat Genet, 46, 812, 10.1038/ng.3040

Milner, 2015, Early-onset lymphoproliferation and autoimmunity caused by germline STAT3 gain-of-function mutations, Blood, 125, 591, 10.1182/blood-2014-09-602763

Haapaniemi, 2015, Autoimmunity, hypogammaglobulinemia, lymphoproliferation, and mycobacterial disease in patients with activating mutations in STAT3, Blood, 125, 639, 10.1182/blood-2014-04-570101

Wienke, 2015, A novel human STAT3 mutation presents with autoimmunity involving Th17 hyperactivation, Oncotarget, 6, 20037, 10.18632/oncotarget.5042

Maffucci, 2016, Genetic diagnosis using whole exome sequencing in common variable immunodeficiency, Front Immunol, 7, 220, 10.3389/fimmu.2016.00220

Lau, 2016, Pulmonary manifestations of the autoimmune lymphoproliferative syndrome. A retrospective study of a unique patient cohort, Ann Am Thorac Soc, 13, 1279, 10.1513/AnnalsATS.201601-079OC

Russell, 2018, A novel de novo activating mutation in STAT3 identified in a patient with common variable immunodeficiency (CVID), Clin Immunol Orlando Fla, 187, 132, 10.1016/j.clim.2017.11.007

Velayos, 2017, An activating mutation in STAT3 results in neonatal diabetes through reduced insulin synthesis, Diabetes, 66, 1022, 10.2337/db16-0867

Sediva, 2017, Short stature in a boy with multiple early-onset autoimmune conditions due to a STAT3 activating mutation: could intracellular growth hormone signalling be compromised?, Horm Res Paediatr, 88, 160, 10.1159/000456544

Nabhani, 2017, STAT3 gain-of-function mutations associated with autoimmune lymphoproliferative syndrome like disease deregulate lymphocyte apoptosis and can be targeted by BH3 mimetic compounds, Clin Immunol Orlando Fla, 181, 32, 10.1016/j.clim.2017.05.021

Khoury, 2017, Tocilizumab promotes regulatory T-cell alleviation in STAT3 gain-of-function–associated multi-organ autoimmune syndrome, Clin Ther, 39, 444, 10.1016/j.clinthera.2017.01.004

Weinreich, 2017, Up, down, and all around: diagnosis and treatment of novel STAT3 variant, Front Pediatr, 5, 49, 10.3389/fped.2017.00049

Gutiérrez, 2018, Partial growth hormone insensitivity and dysregulatory immune disease associated with de novo germline activating STAT3 mutations, Mol Cell Endocrinol, 473, 166, 10.1016/j.mce.2018.01.016

Besnard, 2018, Pediatric-onset Evans syndrome: heterogeneous presentation and high frequency of monogenic disorders including LRBA and CTLA4 mutations, Clin Immunol, 188, 52, 10.1016/j.clim.2017.12.009

Fabre, 2018, STAT3 GOF: a new kid on the block in interstitial lung diseases, Am J Respir Crit Care Med, 197, e22, 10.1164/rccm.201707-1500IM

Takagi, 2018, Genetic heterogeneity of uncharacterized childhood autoimmune diseases with lymphoproliferation, Pediatr Blood Cancer, 65, e26831, 10.1002/pbc.26831

Forbes, 2018, Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutations, J Allergy Clin Immunol, 142, 1665, 10.1016/j.jaci.2018.07.020

Giovannini-Chami, 2019, STAT3 gain of function: a new aetiology of severe rheumatic disease, Rheumatology, 58, 365, 10.1093/rheumatology/key308

Camarero, 2003, Collagenous colitis in children: clinicopathologic, microbiologic, and immunologic features, J Pediatr Gastroenterol Nutr, 37, 508, 10.1097/00005176-200310000-00020